Scholar Rock Holding annual shareholders’ equity
2017
2018
2019
2020
2021
2022
2023
2024
2025
Scholar Rock Holding Shareholders’ Equity Growth & History (SRRK)
Scholar Rock Holding's shareholders’ equity was $245.5M for fiscal 2025.
View full Scholar Rock Holding company overviewScholar Rock Holding annual shareholders’ equity history
| Fiscal year | Period ended | Shareholders’ equity | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $245.5M | −$123.1M | −33.41% |
| 2024 | 2024-12-31 | $368.6M | $143.4M | +63.68% |
| 2023 | 2023-12-31 | $225.2M | −$35.0M | −13.46% |
| 2022 | 2022-12-31 | $260.2M | $88.2M | +51.23% |
| 2021 | 2021-12-31 | $172.1M | −$88.7M | −34.01% |
| 2020 | 2020-12-31 | $260.8M | $147.9M | +130.97% |
| 2019 | 2019-12-31 | $112.9M | $6.3M | +5.89% |
| 2018 | 2018-12-31 | $106.6M | $160.1M | — |
| 2017 | 2017-12-31 | −$53.5M | — | — |
Scholar Rock Holding quarterly shareholders’ equity
Q4.17
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shareholders’ equity | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $253.8M | $20.5M | +8.78% |
| Q1 2026 | 2026-03-31 | $276.0M | −$36.3M | −11.63% |
| Q4 2025 | 2025-12-31 | $245.5M | −$123.1M | −33.41% |
| Q3 2025 | 2025-09-30 | $245.0M | $165.8M | +209.35% |
| Q2 2025 | 2025-06-30 | $233.3M | $99.7M | +74.59% |
| Q1 2025 | 2025-03-31 | $312.3M | $129.6M | +70.89% |
| Q4 2024 | 2024-12-31 | $368.6M | $143.4M | +63.68% |
| Q3 2024 | 2024-09-30 | $79.2M | −$88.5M | −52.77% |
| Q2 2024 | 2024-06-30 | $133.6M | −$68.9M | −34.02% |
| Q1 2024 | 2024-03-31 | $182.8M | −$45.9M | −20.07% |
| Q4 2023 | 2023-12-31 | $225.2M | −$35.0M | −13.46% |
| Q3 2023 | 2023-09-30 | $167.7M | −$125.6M | −42.83% |
| Q2 2023 | 2023-06-30 | $202.5M | −$127.0M | −38.54% |
| Q1 2023 | 2023-03-31 | $228.7M | $57.3M | +33.47% |
| Q4 2022 | 2022-12-31 | $260.2M | $88.2M | +51.23% |
| Q3 2022 | 2022-09-30 | $293.3M | $106.0M | +56.61% |
| Q2 2022 | 2022-06-30 | $329.5M | $112.9M | +52.09% |
| Q1 2022 | 2022-03-31 | $171.3M | −$69.2M | −28.78% |
| Q4 2021 | 2021-12-31 | $172.1M | −$88.7M | −34.01% |
| Q3 2021 | 2021-09-30 | $187.3M | $124.3M | +197.35% |
| Q2 2021 | 2021-06-30 | $216.7M | $134.5M | +163.66% |
| Q1 2021 | 2021-03-31 | $240.5M | $141.9M | +143.84% |
| Q4 2020 | 2020-12-31 | $260.8M | $147.9M | +130.97% |
| Q3 2020 | 2020-09-30 | $63.0M | −$58.8M | −48.29% |
| Q2 2020 | 2020-06-30 | $82.2M | −$46.8M | −36.28% |
| Q1 2020 | 2020-03-31 | $98.6M | $1.1M | +1.15% |
| Q4 2019 | 2019-12-31 | $112.9M | $6.3M | +5.89% |
| Q3 2019 | 2019-09-30 | $121.8M | $19.4M | +19.00% |
| Q2 2019 | 2019-06-30 | $129.0M | $17.3M | +15.54% |
| Q1 2019 | 2019-03-31 | $97.5M | — | — |
| Q4 2018 | 2018-12-31 | $106.6M | $160.1M | — |
| Q3 2018 | 2018-09-30 | $102.3M | — | — |
| Q2 2018 | 2018-06-30 | $111.6M | — | — |
| Q4 2017 | 2017-12-31 | −$53.5M | — | — |
Scholar Rock Holding shareholders’ equity trends
Over the last five fiscal years, Scholar Rock Holding's shareholders’ equity decreased from $260.8M to $245.5M, a change of −$15.3M. The latest reported quarter, Q2 2026, shows $253.8M.
About the metric
What shareholders’ equity means
Shareholders’ equity is the residual accounting value attributable to shareholders after liabilities are subtracted from assets. It can change through earnings, losses, dividends, share issuance, repurchases, and other comprehensive income.
Calculation and source
SEC-reported shareholders’ equity
TickerStat standardizes stockholders’ or shareholders’ equity reported in company SEC filings at each balance-sheet date. Negative equity is retained because it can be economically meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Scholar Rock Holding source filings ↗Community posts
Scholar Rock wins FDA approval for muscle-targeted SMA treatment
Scholar Rock ($SRRK) received FDA approval for ISEMBYLD, its apitegromab treatment for spinal muscular atrophy, in patients aged two and older receiving SMN2-targeted therapy. The company plans to begin shipping the medicine within days. Th ...